Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.50 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL435334 | 0.84 | HSD11B1 (0.71) | HSD11B1CACNA1GSLC6A3SLC6A4S1PR1 | |
| SCHEMBL14944333 | 0.82 | SLC6A4 (0.40) | HSD11B1CACNA1GSLC6A3SLC6A4S1PR1 | |
| SCHEMBL437413 | 0.81 | EPHX2 (0.43) | HSD11B1CACNA1GSLC6A3SLC6A4SLC6A2 | |
| SCHEMBL433244 | 0.80 | SLC6A3 (0.59) | HSD11B1CACNA1GSLC6A3SLC6A4S1PR1 | |
| SCHEMBL436643 | 0.78 | DPP4 (0.52) | HSD11B1CACNA1GSLC6A3SLC6A4SLC6A2 | |
| SCHEMBL12653435 | 0.77 | PSEN1 (0.38) | HSD11B1SLC6A3SLC6A4S1PR1SLC6A2 | |
| SCHEMBL8485828 | 0.76 | DPP4 (0.53) | HSD11B1SLC6A3SLC6A4SLC6A2CYP2C8 | |
| SCHEMBL12000526 | 0.76 | SLC6A3 (0.45) | HSD11B1SLC6A3SLC6A4S1PR1SLC6A2 | |
| SCHEMBL435013 | 0.75 | HSD11B1 (0.68) | HSD11B1CACNA1GSLC6A3SLC6A4S1PR1 | |
| SCHEMBL18440285 | 0.73 | EPHX2 (0.52) | HSD11B1SLC6A3SLC6A4SLC6A2CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187437-B2 | Substituted oxadiazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-17 | — | — | US | disclosed |
| CN-103237795-B | Substituted oxadiazole compounds and their use as S1P1Use of agonists | BRISTOL-MYERS SQUIBB CO. (US) | 2015-10-21 | — | — | CN | disclosed |
| EP-2619190-B1 | SUBSTITUTED OXADIAZOLE COMPOUNDS AND THEIR USE AS S1P1 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2619190-A1 | SUBSTITUTED OXADIAZOLE COMPOUNDS AND THEIR USE AS S1P1 AGONISTS | Bristol-Myers Squibb Company (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20130190361-A1 | SUBSTITUTED OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2012040532-A1 | SUBSTITUTED OXADIAZOLE COMPOUNDS AND THEIR USE AS S1P1 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190361-A1 | SUBSTITUTED OXADIAZOLE COMPOUNDS | S1PR1, S1PR3, S1PR2 | HSD11B1 623/4885CACNA1G 1345/4885SLC6A3 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.